Immunologic response to the survivin-derived multi-epitope vaccine EMD640744 in patients with advanced solid tumors

Abstract

Vaccination with EMD640744 elicited T-cell responses against survivin peptides in the majority of patients, demonstrating the immunologic efficacy of EMD640744.

Immune responses in the thyroid cancer microenvironment: making immunotherapy a possible mission

“…Survivin has been shown to be differentially expressed in various subtypes of malignant human thyroid cancers when compared to benign and healthy thyroid tissues via reverse transcriptase-PCR (Chen et al 2012, Waligórska-Stachura et al 2014. Indeed, peptide-based survivin vaccines are being explored in various human solid cancer clinical trials (Miyazaki et al 2011, Becker et al 2012, Lennerz et al 2014, and may be aptly suited for thyroid cancers. In one study, human epidermal growth factor receptor-2 was found to be overexpressed in 44% of follicular thyroid tumors (n = 45) and 18% of papillary thyroid tumors (n = 45) (Ruggeri et al 2016).…”

Novel cancer antigens for personalized immunotherapies: latest evidence and clinical potential

“…Peptide cancer vaccines targeting survivin have been evaluated in phase I and phase II clinical trials. A phase I study of a multi-epitope anti-survivin peptide vaccine (EMD640744) in patients with advanced solid tumors found an antigen-specific T-cell response in 63% of subjects, and 28% of vaccinated subjects achieved stable disease [Lennerz et al 2014]. Another phase I study in pediatric brainstem glioma patients using a tripeptide vaccine containing survivin and given in combination with the immunoadjuvant poly-ICLC (polyinosinicpolycytidylic acid stabilized by lysine and carboxymethylcellulose) showed evidence of survivinspecific immune responses and clinical benefit [Pollack et al 2014].…”

Trial Watch: Peptide-based anticancer vaccines

“…[153][154][155] Patients affected by virtually all types of neoplasms have been enrolled in these clinical trials, including (but not limited to) various hematological malignancies, which is highly expressed by a wide panel of malignancies; [173][174][175] Wilms' tumor 1 (WT1), 90,111,122,125 which is expressed to elevated levels by (at least some variants of) colorectal carcinoma, melanoma, acute myeloid leukemia. [176][177][178][179] In addition, several of these trials tested the safety and therapeutic activity of mixtures comprising up to 12-15 distinct TAA-derived peptides, 91,100,102,103,105,106,113,120,121,123,124,[128][129][130]133,136,140,141,147,150 or "personalized peptide vaccination" (PPV), i.e., the administration of one or more peptides derived from TAAs against which the patient have previously (naturally or in response to other therapies) developed an immune response. Taken together, the results of these studies corroborate the notion that TAA-derived peptides as well as full length TAAs and SLPs are well tolerated by cancer patients, the most common side effects associated with this immunotherapeutic paradigm being skin reactions at the injection site, fatigue and nausea.…”